Loading...

DXCM - DexCom, Inc.

Analyst Small Caps Signal for 09-12-2018
Analyst Upgrade Signal: DXCM from Under Perform to Market Perform by Northland Capital
Price Target: $


Loading Chart DXCM

Stock Signal Information


Signal

Analyst Upgrade Signal: DXCM from Under Perform to Market Perform by Northland Capital
Price Target: $
Report Date: 09-12-2018
Symbol: DXCM - DexCom, Inc.
Sector: Healthcare
Industry: Diagnostics & Research
Analyst Upgrade Signal: DXCM from Under Perform to Market Perform by Northland Capital
Price Target: $

  DXCM Technical Analysis

Company Contact

DexCom, Inc. (DXCM)
6340 Sequence Dr
San Diego, CALIFORNIA 92121
Phone: 18582000200
Website: http://www.dexcom.com
CEO: Mr. Kevin Sayer

DXCM, DexCom, Inc.

DXCM DexCom, Inc. Logo Image

NASDAQ, Nasdaq Global Select


Company Profile

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.